Editorials

It Takes a Village to Craft a Clinical Guideline
W.N. Roberts, M.H. Liang ........................................ 2123

Effect of Anti-Tumor Necrosis Factor on Work Disability
S.M.M. Verstappen, J.W.G. Jacobs, K.L. Hyrich ..... 2126

Tumor Necrosis Factor Inhibition in the Treatment of Refractory Sarcoidosis: Slaying the Dragon?
N.J. Sweiss, R.P. Baughman .......................... 2129

The Value of Measuring Variability in Osteoarthritis Pain
K.D. Allen .................................................. 2132

Articles

T Cells Against the Pathogenic and Protective Epitopes of HSP65 Are Crossreactive and Display Functional Similarity: Novel Aspect of Regulation of Autoimmune Arthritis
M. Durai, H.R. Kim, K. Bala, K.D. Moudgil .............. 2134

Antinflammatory Mediator LXA4 and Its Receptor in Synovitis of Patients with RA
A. Hashimoto, I. Hayashi, Y. Murakami, et al ......... 2144

Bone Edema Determined by MRI Reflects Severe Disease Status in Patients with Early-Stage RA

Increased TNF-α mRNA Expression in Whole Blood from Patients with RA: Reduction After Infliximab Treatment Does Not Predict Response
A. Pachot, B. Arnaud, H. Marrote, et al ................. 2158

Intracellular Oxidative Activation in SF Neutrophils from Patients with RA But Not from Other Arthritis Patients

Upregulation of Kallistatin Expression in Rheumatoid Joints

Association of Anemia and Physical Disability Among Patients with RA
C. Han, M.U. Rahman, M.K. Doyle, et al ............... 2177

Are the 2002 ACR Guidelines for the Management of RA Being Followed in Canada’s Largest Academic Rheumatology Center?
C.R. Kitamura, G. Rohekar, V.P. Bykerk, S. Carette ...... 2183

Advantages and Limitations of Utility Assessment Methods in RA
A. Beresniak, A.S. Russell, B. Haraoui, L. Bessette, C. Bombardier, G. Duru ............... 2193

Leflunomide-Associated Infections in RA

Abatacept Binds to the Fc Receptor CD64 But Does Not Mediate Complement-Dependent Cytotoxicity or Antibody-Dependent Cellular Cytotoxicity
P.M. Davis, R. Abraham, L. Xu, S.G. Nadler, S.J. Suchard ......................... 2204

The Prevalence and Incidence of Work Disability in RA, and the Effect of Anti-TNF on Work Disability
F. Wolfe, S. Allaire, K. Michaud ......................... 2211

Hypocomplementemia in SSc — Clinical and Serological Correlations
M. Hudson, J.G. Walker, M. Fritzler, S. Taillefer, Canadian Scleroderma Research Group, M. Baron ......................... 2218

Elevated Plasma Adrenomedullin and Vascular Manifestations in Patients with SSc
M.Y. Mok, B.M.Y. Cheung, Y. Lo, R.Y.H. Leung, W.S. Wong, C.S. Lau ......................... 2224

Pulmonary Arterial Hypertension and Severe Pulmonary Fibrosis in SSc Patients with a Nucleolar Antibody
V.D. Steen, M. Lucas, N. Fertig, T.A. Medsger Jr ......................... 2230

Estimating the Burden of Scleroderma Disease in Spain

Immunization with DNA Topoisomerase I Induces Autoimmune Responses But Not Scleroderma-like Pathologies in Mice
P.Q. Hu, A.A. Hurwitz, J.J. Oppenheim ......................... 2243

Anticentromere Antibodies Identify Patients with SS and Autoimmune Overlap Syndrome

Joint Pain with Aromatase Inhibitors: Abnormal Frequency of SS
S. B. De Lafontan, H. Roché ......................... 2259

In Vitro Observations of T Cell Responsiveness to Recall Antigens During TNF-α-Blocking Therapy in Patients with AS

Contents continued opposite inside back cover . . .